M
Merryn Voysey
Researcher at University of Oxford
Publications - 154
Citations - 20211
Merryn Voysey is an academic researcher from University of Oxford. The author has contributed to research in topics: Vaccination & Randomized controlled trial. The author has an hindex of 36, co-authored 134 publications receiving 11913 citations. Previous affiliations of Merryn Voysey include National Health and Medical Research Council & Southampton General Hospital.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials
Borislava Mihaylova,Jonathan Emberson,L Blackwell,Anthony C Keech,John Simes,Elizabeth H Barnes,Merryn Voysey,Alastair Gray,Rory Collins,Colin Baigent +9 more
TL;DR: Reduction of LDL cholesterol with a statin reduced the risk of major vascular events, largely irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all-cause mortality.
Journal ArticleDOI
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
P M Folegatti,Katie J. Ewer,Parvinder K. Aley,Brian Angus,Stephan Becker,Sandra Belij-Rammerstorfer,D Bellamy,S Bibi,M Bittaye,Elizabeth A. Clutterbuck,Christina Dold,Saul N. Faust,Adam Finn,Amy Flaxman,Bassam Hallis,Paul T. Heath,D Jenkin,Rajeka Lazarus,R Makinson,Angela M. Minassian,Katrina M Pollock,M N Ramasamy,Hannah Robinson,Matthew D. Snape,R Tarrant,Merryn Voysey,Catherine M. Green,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +31 more
TL;DR: A phase 1/2, single-blind, randomized controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control was conducted.
Journal ArticleDOI
Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher,Rachel O'Connell,Merryn Voysey,Jonathan Emberson,L Blackwell,Borislava Mihaylova,John Simes,Rory Collins,Adrienne Kirby,Helen M. Colhoun,Eugene Braunwald,J La Rosa,Terje R. Pedersen,Andrew Tonkin,Barry R. Davis,Peter Sleight,MariaGrazia Franzosi,Colin Baigent,Anthony C Keech +18 more
TL;DR: In men and women at an equivalent risk of cardiovascular disease, statin therapy is of similar effectiveness for the prevention of major vascular events.
Journal ArticleDOI
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
M N Ramasamy,Angela M. Minassian,Katie J. Ewer,Amy Flaxman,P M Folegatti,Daniel R Owens,Merryn Voysey,Parvinder K. Aley,Brian Angus,G Babbage,Sandra Belij-Rammerstorfer,L Berry,S Bibi,M Bittaye,Katrina Cathie,H Chappell,Sue Charlton,P Cicconi,Elizabeth A. Clutterbuck,R Colin-Jones,Christina Dold,Emary Krw.,Sofiya Fedosyuk,Michelle Fuskova,Diane Gbesemete,Christopher A Green,Bassam Hallis,M M Hou,D Jenkin,Joe Ccd.,Elizabeth J. Kelly,S Kerridge,Alison M. Lawrie,A Lelliott,May Nwe Lwin,R Makinson,N G Marchevsky,Y Mujadidi,Munro Aps.,M Pacurar,E Plested,J Rand,Thomas A. Rawlinson,S Rhead,Hannah Robinson,Adam J. Ritchie,A L Ross-Russell,Stephen Saich,Nisha Singh,Catherine C. Smith,Matthew D. Snape,R Song,R Tarrant,Yrene Themistocleous,Kelly M. Thomas,Tonya Villafana,Sarah Warren,Watson Mee.,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Saul N. Faust,Andrew J. Pollard +63 more
TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.